Harrow's earnings show robust growth, but challenges remain. Discover why its valuation and growth targets led to an upgrade ...

Harrow, Inc. offers speculative gains from $20s to $30s, with Q4 growth, bullish 2025 revenue guidance, and long-term growth ...

Harrow (NASDAQ:HROW) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings ...

Harrow Inc (HROW) reports an 84% increase in Q4 revenue, driven by strong product performance and strategic programs, despite challenges in reporting and cash flow management. NASHVILLE, Tenn ...

NASHVILLE, Tenn. (AP) — NASHVILLE, Tenn. (AP) — Harrow, Inc. (HROW) on Thursday reported profit of $6.8 million in its fourth quarter. The Nashville, Tennessee-based company said it had net income of ...

Reports Q4 revenue $66.8M, consensus $61.8M. “Our stellar fourth-quarter performance, including an 84% year-over-year increase in revenues to a ...

These preliminary results remain subject to the completion of the financial closing procedures and the final review by Harrow’s independent auditors. Accordingly, actual results may differ from ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter ...